why choose us

First received: June 05, 2023

Clinical Trial: Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients

Study Status: ACTIVE_NOT_RECRUITING

Recruit Status: ACTIVE_NOT_RECRUITING

Condition: Multiple Sclerosis, Relapsing-Remitting

Study Type: INTERVENTIONAL


Official Title: Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients

Brief Summary: Multiple sclerosis (MS) is a chronic, immune-mediated, demyelinating disease of the central nervous system.Typical brain lesions of the disease may be partially repaired by an endogenous remyelination process which is limited and tends to deplete over the course of the disease.Cladribine tablets are an approved treatment that promotes selective lymphocyte depletion, reducing the inflammatory activity of the disease.The present study is based on the hypothesis that improved inflammatory control through cladribine…

Read more